Artelo Biosciences Inc. (ARTL) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Artelo Biosciences Inc. (NASDAQ: ARTL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $2.22 (-3.90% 1D, market cap $1.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ARTL ranks #518 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ARTL carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SPRC (SciSparc Ltd.) holds a D+ grade (55/100 RQD, P/E N/A, ROIC —, cap $1.5M) and GNPX (Genprex Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $1.7M). Among the 5-stock peer group, ARTL leads on earnings multiple (N/A) while ARTL leads on capital efficiency (-35.0% ROIC).
Per ARTL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001621221), Artelo Biosciences Inc. generated $0 in revenue, -$12.9M in net income, and -$8.5M in free cash flow against $2.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 28.9 (OVERSOLD (<32))
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While ARTL currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.29) and Max Pain ($2.33) forces dealer call-delta covering toward $188.15.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Artelo Biosciences Inc. (ARTL) dropped -3.90% to $2.22, trading at 2% of its 52-week range ($2.05 – $179.19). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Artelo Biosciences Inc. (ARTL) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Artelo Biosciences Inc. (ARTL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Artelo Biosciences Inc. (ARTL) market action, institutional positioning, and fundamental catalysts.
The Manila Times report covering Artelo Biosciences Inc. (ARTL) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Artelo Biosciences Inc. (ARTL) market action, institutional positioning, and fundamental catalysts.
Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with
Presentation will introduce ART26.12, the first selective FABP5 inhibitor to enter human clinical studies, to the world’s largest gathering of pain professionals Growing body of data supports ART26.12’s potential as a no
Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ARTL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ARTL. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Artelo Biosciences Inc. (ARTL) ranks #518 by composite RQD confidence (41/100, grade D-) and #1015 by equity capitalization ($1.3M). Within this direct 5-issuer industry benchmark cohort, ARTL leads on earnings valuation at N/A trailing P/E, while ARTL leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PPBT currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with ARTL at 41/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ARTL
ACTIVE
Artelo Biosciences Inc. | D- | 41/100 | — | — | -35.0% | -3.90% | $1.3M | Benchmark Subject |
| SPRC SciSparc Ltd. | D+ | 55/100 | — | — | — | -5.05% | $1.5M | /sprc-vs-artl → |
| GNPX Genprex Inc. | D | 47/100 | — | — | -35.0% | +9.80% | $1.7M | /gnpx-vs-artl → |
| OGEN Oragenics Inc. | D | 44/100 | — | — | -35.0% | -0.05% | $1.7M | /ogen-vs-artl → |
| PPBT Purple Biotech Ltd. | C- | 61/100 | — | — | — | +7.34% | $1.8M | /ppbt-vs-artl → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Artelo Biosciences Inc. (ARTL) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$12.9M, operating cash flow of -$8.5M, and free cash flow of -$8.5M (-2.0% YoY). On the balance sheet, ARTL closed FY2025 with $2.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$12.9M | -$8.5M | -$8.5M | $2.8M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$9.8M | -$8.3M | -$8.3M | $4.7M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$9.3M | -$8.2M | -$8.2M | — | — |
As of 2026-11-02, Artelo Biosciences Inc. (NASDAQ: ARTL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $2.22 (-3.90% 1D, market cap $1.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ARTL ranks #518 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ARTL carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, SPRC (SciSparc Ltd.) holds a D+ grade (55/100 RQD, P/E N/A, ROIC —, cap $1.5M) and GNPX (Genprex Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $1.7M). Among the 5-stock peer group, ARTL leads on earnings multiple (N/A) while ARTL leads on capital efficiency (-35.0% ROIC).
Per ARTL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001621221), Artelo Biosciences Inc. generated $0 in revenue, -$12.9M in net income, and -$8.5M in free cash flow against $2.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ARTL last traded at $2.22 (-3.90% on volume of 12,436 shares), positioning the stock -48.25% below its 50-day simple moving average ($4.29) and -89.80% below its 200-day simple moving average ($21.77). Across its 52-week range of $2.05 to $179.19, ARTL sits at the 0.1% percentile with a 14-day RSI of 28.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.94 to $2.50).
Why ARTL Stock dropped -3.90% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, ARTL scores 41 / 20 overall, graded D- and labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Pillar scores are: Fundamental Cash Engine 8/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow 8/20 (institutional accumulation and options positioning), Insider Conviction 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 10/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 10/20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5). For a prospective investor, the weakest pillars are cash generation and insider conviction, both of which point to limited internal support for the equity. The forensic pillar is mid-range rather than strong, and the Piotroski reading of 1/9 signals weak financial-health indicators. The Beta of 1.0 places the stock in line with the market on volatility, but the rating frames downside risk as coming mainly from balance-sheet fragility and negative cash flow rather than from market beta. Valuation tradeoffs are difficult to assess from the source data because P/E, EPS, and EV/EBITDA are not available. Any upside argument therefore rests on non-financial catalysts rather than on earnings or cash-flow recovery visible in the provided figures.
Artelo Biosciences Inc. (ARTL) is a NASDAQ-listed issuer classified in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the Profile section. Per the Recent News section, the company describes a novel FABP5 inhibitor platform and presents preclinical and clinical-stage pain candidate data, including ART27.13 in chemotherapy-induced neuropathic pain. Per the Profile section, the market capitalization is listed as $0.0B. Revenue is reported as $0.0M in each of the three reported fiscal years, so commercial revenue generation is not evident in the provided financials. Information on customers and monetization mechanisms is not available in source data.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-11.4M | $-12.9M | N/A | $-8.5M | $0.6M | N/A |
| FY 2024 | $0.0M | $-10.1M | $-9.8M | N/A | $-8.3M | N/A | N/A |
| FY 2023 | $0.0M | $-9.9M | $-9.3M | N/A | $-8.2M | N/A | N/A |
Per the SEC financials, the company reported operating losses and negative free cash flow in each period shown, with gross, operating, and net margins all listed at 0% in the Market Data section. Per the Market Data section, ROIC is -35% and FCF yield is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 1/9, and Debt/Equity is 0.5. The FY 2025 cash balance of $0.6M is the only cash figure reported, and it is small relative to the FY 2025 free cash outflow of $-8.5M. Debt for the periods shown is listed as N/A.
Per the Recent News section, several headlines reference company presentations and data releases. These include selection for a first-ever company presentation at BIO-Europe 2026, showcasing clinical progress and its FABP5 inhibitor platform; a report that no serious medical problems were attributed to its pain candidate in a first human study; and planned presentation of ART27.13 data at the IASP 2026 World Congress on Pain. A separate headline references a seasonal returns chart, and another is a price-prediction piece. All items are tagged YELLOW with the impact label MARKET WIRE, and no proprietary signals are attached to them. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Risk watch items include dependence on clinical-stage programs for which financial outcomes are not provided, and a 52-week range of $2.05 - $179.19 that indicates extreme price volatility within the period.
Real-time company headlines, analyst actions, and sector developments for Artelo Biosciences Inc. (ARTL) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Artelo Biosciences Inc. (ARTL) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance UK report covering Artelo Biosciences Inc. (ARTL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Artelo Biosciences Inc. (ARTL) market action, institutional positioning, and fundamental catalysts.
The Manila Times report covering Artelo Biosciences Inc. (ARTL) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Artelo Biosciences Inc. (ARTL) market action, institutional positioning, and fundamental catalysts.
Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with
Presentation will introduce ART26.12, the first selective FABP5 inhibitor to enter human clinical studies, to the world’s largest gathering of pain professionals Growing body of data supports ART26.12’s potential as a no
Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with
Welcome to the ARTL (Artelo Biosciences Inc.) Roar Pit. Current RQD Composite is 41/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ARTL, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Artelo Biosciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ARTL, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $2.22 (52-wk range $2.05 - $179.19), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).